Your shopping cart is currently empty

TAT-MEK1, an inhibitor of ERK2, comprises TAT and MEK1 (N-terminal). The TAT component (YGRKKRRQRRR) is a cell-penetrating peptide derived from the human immunodeficiency (HIV-1) transcriptional trans activator (TAT). TAT-MEK1 has an IC50 of 29 μM for ERK2 in vitro [1] [2].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | TAT-MEK1, an inhibitor of ERK2, comprises TAT and MEK1 (N-terminal). The TAT component (YGRKKRRQRRR) is a cell-penetrating peptide derived from the human immunodeficiency (HIV-1) transcriptional trans activator (TAT). TAT-MEK1 has an IC50 of 29 μM for ERK2 in vitro [1] [2]. |
| In vitro | TAT-MEK1 (100 μM, 30 min) effectively inhibits luciferase activity in NIH 3T3 and PC12 cells and suppresses ERK2 activation [2]. Western Blot Analysis [2] was conducted on cell lines NIH 3T3 and PC12 with a concentration of 100 μM and an incubation time of 30 minutes, resulting in decreased luciferase and ERK2 activities. |
| Molecular Weight | 3146.77 |
| Formula | C136H241N53O31S |
| Cas No. | 566872-16-0 |
| Smiles | C([C@@H](NC([C@@H](NC([C@@H](NC(=O)[C@H]1N(C([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@H](CC2=CC=C(O)C=C2)NC(CN)=O)=O)=O)CCCNC(=N)N)=O)CCCCN)=O)CCCCN)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CCC(N)=O)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)=O)CCSC)=O)CCC1)CCCCN)=O)CCCCN)=O)CCCCN)(=O)N3[C@H](C(N[C@H](C(=O)N4[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)N5[C@H](C(N)=O)CCC5)CC(N)=O)=O)CC(C)C)=O)CCC(N)=O)=O)[C@H](CC)C)=O)CCC4)[C@@H](C)O)=O)CCC3 |
| Sequence | Gly-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Gly-Met-Pro-Lys-Lys-Lys-Pro-Thr-Pro-Ile-Gln-Leu-Asn-Pro-NH2 |
| Sequence Short | GYGRKKRRQRRRGMPKKKPTPIQLNP |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.